Failure of chemotherapy for pancreatic cancer can change the chemotherapy regimen, or conduct radiotherapy, targeted therapy and immunotherapy. Pancreatic cancer has a highly malignant biological behavior, and patients still have a high risk of tumor recurrence after surgery, and some patients have local recurrence or distant metastasis in the early postoperative period. Moreover, chemotherapy is mostly used to relieve symptoms, improve quality of life and prolong survival, and it is only a regimen for controlling the progression of the disease, which can continue to progress in most patients. If chemotherapy fails, the following options can be taken: 1. further evaluation of the disease, such as genetic testing, etc., to choose other chemotherapy programs to control the disease; 2. Radiotherapy, either systemic or localized, to control the progression of the cancer, shrink the tumor, stabilize the disease and prolong the survival cycle. 3. Targeted therapy, if the patient has a gene mutation, there are targeted drugs that can be used for targeted therapy, such as larotrectinib, entrectinib, erlotinib and so on. 4. Immunotherapy, immune checkpoint inhibitors such as PD-1 monoclonal antibodies are currently recommended for the treatment of metastatic pancreatic cancer patients with high microsatellite instability (MSI-H) or mismatch repair defective (dMMR) molecular features. Other treatments include radiofrequency ablation, cryotherapy, high-energy focused ultrasound, gamma knife, and radioactive particle implantation. If pancreatic cancer is suspected or diagnosed, it is recommended to go to a regular hospital for comprehensive assessment of the disease, integrating multiple means of diagnosis and assessment of the disease, and cooperate with the treatment as prescribed by the doctor, so as to avoid delaying the disease. Please strictly follow the doctor’s prescription for medication, and do not use medication on your own.